comparemela.com
Home
Live Updates
Scandion Oncology successfully completes the dose finding wi
Scandion Oncology successfully completes the dose finding wi
Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial)
The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapies gemcitabine and nab-paclitaxel in patients with... | March 31, 2023
Related Keywords
Copenhagen ,
Køavn ,
Denmark ,
Sweden ,
Johnny Stilou ,
Alfredo Zurlo ,
Cancer Drug Resistance Company ,
Scandion Oncology ,
Chief Medical Officer ,
Drug Resistance Company ,
Nasdaq First North Growth Market Sweden ,
Hamnen Corporate Finance ,
Nasdaq First North Growth ,
Scandion Oncologyas Stock Exchange ,
News ,
Information ,
Press Release ,
The ,
Primary ,
Ndpoint ,
Gas ,
Establishing ,
Maximum ,
Ctolerated ,
Nose ,
F ,
N ,
Combination ,
Ith ,
Standard ,
Chemotherapies ,
Gemcitabine ,
End ,
Atients Scol Dk0061031895 ,